Argireline side effects and risks

Reported side effects

• Stinging or burning: AH8 cream: stinging 2/7 (29%), burning 1/7 (14%); placebo burning 2/7 (29%)., mild. Stop if persistent; check the whole formula for irritants. (source)
• Itchy or dry skin: AH8 cream: itch 1/7 (14%), dryness 1/7 (14%); placebo itch 2/7, dryness 1/7., mild. Pause the product and seek advice if the rash continues. (source)
• Eyelid irritation: In the 0.005% spasm pilot: 2/12 active and 2/12 placebo (16.7% each)., mild. Stop eye-area use if irritation develops. (source)
• Contact dermatitis from a combination routine: 1/16 stopped the 2026 multi product/toxin study after eyelid misapplication. AH8 causality is unknown., moderate. Stop the product; seek assessment for a lasting rash. (source)
• Serious infection after injection: One published M. abscessus case; no rate can be calculated. This was facial injection, not topical use., serious. Prompt specialist assessment for persistent nodules or abscesses. (source)

Stop and get help if

• Trouble breathing, faintness, or face/throat swelling after a product: Stop use and seek emergency care now.
• Persistent or spreading facial nodules, pus or abscesses after an injection: Seek prompt medical care; report the injection and possible unusual infection.
• Eye pain, marked swelling or a new vision problem after eye-area use: Stop the product and seek urgent eye assessment.

Who should avoid it

• pregnant: No pregnancy safety data established. Pregnant people were excluded from cosmetic trials; This is a precaution.
• breastfeeding: No breastfeeding safety data established; nursing people were excluded from trials. This is a precaution.
• tryingToConceive: People trying to conceive were excluded from the crow’s-feet trial. This is a precaution; harm has not been demonstrated.
• under18: No pediatric cosmetic safety or dosing evidence located.
• other: Avoid a formula that previously caused an allergic reaction. Preservatives and fragrances can also be responsible.
• other: Cosmetic creams and powders are not established injection products. A serious facial injection infection is published.
• other: Damaged-skin absorption and irritation are not established. Relevant skin disease was excluded from cosmetic trials.
• other: CIR found insufficient cosmetic safety data above 0.005% actual peptide. A diluted ingredient percentage is a different measure.
• testedAthlete: Not named in the 2026 List; S0 may matter for unapproved pharmacological use. Obtain a product- and route-specific ruling.

Interactions

• Botulinum toxin products: Small add-on studies exist, but a reliable extra effect or interaction risk is unproven. Tell the injector about the whole routine.
• Other wrinkle peptides and multi-active skin routines: Extra benefit and interaction rates are unknown. Clinical inference: more products make the cause of irritation harder to identify.

Product quality risks

• Actual peptide content may differ from the front-label ingredient-solution percentage.
• An FDA research report screened 77 cosmetics and reported only 33% had detectable AH8 despite claims; sampling details were limited.
• Published mass-spectrometry work examined ingredient identity and oxidation products.
• Bacterial contamination can affect cosmetics; an AH8 facial-injection case caused persistent abscesses.